Overview

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Status:
Completed

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

2,4-thiazolidinedione
Acetohexamide
Antibodies, Monoclonal
Chlorpropamide
Glimepiride
Glipizide
Glyburide
Insulin
Insulin Lispro
Insulin, Globin Zinc
Insulin, Isophane
Insulin, Regular, Pork
Metformin
Tolazamide
Tolbutamide
Troglitazone